

<b>LABEL 50 ml</b>
--------------------

1. **NAME OF THE VETERINARY MEDICINAL PRODUCT**

The UK, Ireland,	Marbocyl Solo 10% solution for injection for cattle
Spain	Marbocyl Bovinos 100 mg/ml solution for injection for cattle
Germany, Austria, The Netherlands, Belgium, Italy, Poland, Portugal, The Slovak Republic, The Czech Republic, Greece, Luxembourg, France	Marbocyl S 10% solution for injection

2. **QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Marbofloxacin.....100.0 mg/ml

3. **CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

50 ml

4. **ROUTE(S) OF ADMINISTRATION**

Intramuscular use

5. **WITHDRAWAL PERIOD**

Meat and offal: 3 days  
Milk : 72 hours

6. **BATCH NUMBER**

Lot:

7. **EXPIRY DATE**

Exp:  
Shelf life after first opening the immediate packaging: 28 days  
Once opened, use by

8. **THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

<b>LABEL 100 ml and 250 ml</b>
--------------------------------

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

The UK, Ireland,	Marbocyl Solo 10% solution for injection for cattle
Spain	Marbocyl Supra 100 mg/ml solution for injection for cattle
Germany, Austria, The Netherlands, Belgium, Italy, Poland, Portugal, The Slovak Republic, The Czech Republic, Greece, Luxembourg, France	Marbocyl S 10% solution for injection

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Marbofloxacin ..... 100.0 mg

Disodium edetate.....0.1 mg

Thioglycerol .....1.0 mg

metacresol .....2.0 mg

Excipient to .....1 ml

**3. PHARMACEUTICAL FORM**

Solution for injection.

**4. PACKAGE SIZE**

100 ml vial

250 ml vial

**5. TARGET SPECIES**

Cattle

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Intramuscular use.

Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

Meat and offal: 3 days

Milk: 72 hours

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use

**10. EXPIRY DATE**

Exp:

Shelf life after first opening the immediate packaging: 28 days

Once opened, use by

**11. SPECIAL STORAGE CONDITIONS**

Protect from light.

This veterinary medicinal product does not require any special temperature storage conditions.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Not requested on the immediate label.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable**

FOR ANIMAL TREATMENT ONLY

TO BE SUPPLIED ONLY ON VETERINARY PRESCRIPTION

**14. THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”**

Not requested on the immediate label.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Refer to Appendix 1

**16. MARKETING AUTHORISATION NUMBER(S)**

**17. MANUFACTURER’S BATCH NUMBER**

Lot:

**BOX**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

The UK, Ireland,	Marbocyl Solo 10% solution for injection for cattle
Spain	Marbocyl Bovinos 100 mg/ml solution for injection for cattle
Germany, Austria, The Netherlands, Belgium, Italy, Poland, Portugal, The Slovak Republic, The Czech Republic, Greece, Luxembourg, France	Marbocyl S 10% solution for injection

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Marbofloxacin ..... 100.0 mg

Disodium edetate.....0.1 mg

Thioglycerol ..... 1.0 mg

metacresol ..... 2.0 mg

Excipient to ..... 1 ml

**3. PHARMACEUTICAL FORM**

Solution for injection.

**4. PACKAGE SIZE**

Box containing one 50 ml vial  
Box containing one 100 ml vial  
Box containing one 250 ml vial

**5. TARGET SPECIES**

Cattle

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Intramuscular use.  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

Meat and offal: 3 days  
Milk : 72 hours

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

Exp:

Shelf life after first opening the immediate packaging: 28 days

**11. SPECIAL STORAGE CONDITIONS**

Protect from light.

This veterinary medicinal product does not require any special temperature storage conditions.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Any unused product or waste material should be disposed of in accordance with national requirements

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable**

FOR ANIMAL TREATMENT ONLY

TO BE SUPPLIED ONLY ON VETERINARY PRESCRIPTION

**14. THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”**

Keep out of the reach and sight of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Refer to Appendix 1

**16. MARKETING AUTHORISATION NUMBER(S)**

**17. MANUFACTURER’S BATCH NUMBER**

Lot:

## LEAFLET

The UK, Ireland,	Marbocyl Solo 10% solution for injection for cattle
Spain	Marbocyl Bovinos 100 mg/ml solution for injection for cattle
Germany, Austria, The Netherlands, Belgium, Italy, Poland, Portugal, The Slovak Republic, The Czech Republic, Greece, Luxembourg, France	Marbocyl S 10% solution for injection

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Please refer to Appendix 1

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

The UK, Ireland,	Marbocyl Solo 10% solution for injection for cattle
Spain	Marbocyl Bovinos 100 mg/ml solution for injection for cattle
Germany, Austria, The Netherlands, Belgium, Italy, Poland, Portugal, The Slovak Republic, The Czech Republic, Greece, Luxembourg, France	Marbocyl S 10% solution for injection

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)**

Marbofloxacin .....100.0 mg

Disodium edetate.....0.1 mg

Thioglycerol .....1.0 mg

metacresol .....2.0 mg

Excipient to .....1 ml

**4. INDICATION(S)**

Therapeutic treatment of respiratory infections caused by sensitive strains of *Pasteurella multocida*, *Mannheimia haemolytica* and *Histophilus somni*.

**5. CONTRAINDICATIONS**

Do not use in animals with known hypersensitivity to fluoroquinolones.

Do not use in cases where the pathogen involved is resistant to other fluoroquinolones (cross resistance).

**6. ADVERSE REACTION**

Fluoroquinolones are known to induce arthropathies. Nevertheless, this effect has never been observed with marbofloxacin in cattle.

Administration by the intramuscular route may cause transient local reactions such as pain and swelling at the injection site and inflammatory lesions which may persist for at least 12 days after injection. No other adverse effect was observed on cattle.

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

**7. TARGET SPECIES**

Cattle

**8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

The recommended dosage is 8 mg/kg body weight i.e. 2 ml /25kg body weight in a single intramuscular injection  
If the volume to be injected is more than 20 ml, it should be divided between two or more injection sites.

**9. ADVICE ON CORRECT ADMINISTRATION**

Use of the product should be based on susceptibility testing and has to take into account official and local antimicrobial policies.  
It is prudent to reserve the fluoroquinolones for the treatment of clinical conditions that have responded poorly, or are expected to respond poorly, to other classes of antibiotics.

**10. WITHDRAWAL PERIOD**

Meat and offal: 3 days  
Milk: 72 hours

**11. SPECIAL STORAGE PRECAUTIONS**

Protect from light.  
This veterinary medicinal product does not require any special temperature storage conditions.  
Keep out of the reach and sight of children.  
Shelf-life after first opening the **immediate packaging**: 28 days.  
When the container is broached (opened) for the first time, using the in-use shelf-life which is specified on this package leaflet, the date on which any product remaining in the container should be discarded should be worked out. This discard date should be written in the space provided on the label.

**12. SPECIAL WARNINGS**

Official and local antimicrobial policies should be taken into account when the product is used.  
Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials.  
Whenever possible, fluoroquinolones should only be used based on susceptibility testing.  
Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.

People with known hypersensitivity to quinolones should avoid any contact with the product.  
If the product comes into contact with the skin or eyes, rinse with copious amounts of water.  
Accidental self-injection can induce a slight irritation.

Laboratory studies in rats and rabbits have not produced any evidence of a teratogenic, embryotoxic or maternotoxic effect associated with the use of marbofloxacin. Safety of the product at 8 mg/kg has not been determined in pregnant cows or in suckling calves when used in cows. Use only accordingly to the benefit/risk assessment by the responsible veterinarian.

No sign of overdosage has been observed after administration of 3 times the recommended dose. Overdosage may cause signs such as acute neurological disorders which should be treated symptomatically.

Do not mix with other medicinal products

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Any unused veterinary medicinal product or waste material derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

**15. OTHER INFORMATION**

Pack sizes: vial of 50, 100, 250 ml  
Not all pack sizes may be marketed

## **APPENDIX 1**

### **MARBOCYL S<sup>®</sup>**

Solution for injection  
**MRP n° FR/V/168/01/MR**

#### **MARKETING AUTHORISATION HOLDER**

<b>FR/PT/LU/IT/EL/PL</b>	<b>VETOQUINOL S.A.</b> Magny-Vernois, BP 189 F-70204 LURE CEDEX (FRANCE)
<b>AUSTRIA</b>	<b>VETOQUINOL ÖSTERREICH GmbH</b> Zehetnergasse 24 A-1140 WIEN (AUSTRIA)
<b>GERMANY</b>	<b>VETOQUINOL GmbH</b> Parkstrasse 10 88212 RAVENSBURG (GERMANY)
<b>BELGIUM</b>	<b>VETOQUINOL S.A. - N.V.</b> Kontichsesteenweg 42 B-2630 AARSELAAR (BELGIUM)
<b>THE NETHERLANDS</b>	<b>VETOQUINOL B.V.</b> Postbus 3191, 5203 DD 'S-HERTOGENBOSCH (THE NETHERLANDS)
<b>SK/CZ</b>	<b>VETOQUINOL s.r.o.</b> Zamecnicka 411 28802 NYMBURK (CZECH REPUBLIC)
<b>SPAIN</b>	<b>VETOQUINOL ESPECIALIDADES VETERINARIAS</b> Parque Empresarial San Fernando, Edificio Italia 28830 SAN FERNANDO DE HENARES, MADRID (SPAIN)
<b>UK/IE</b>	<b>VETOQUINOL UK Ltd</b> Vetoquinol House Great Slade Buckingham Industrial Park Buckingham MK18 1PA (UNITED-KINGDOM)

#### **MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**

VETOQUINOL S.A.  
Magny-Vernois, BP 189  
F-70204 LURE CEDEX  
FRANCE